Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of transurethral split of prostate for benign prostatic hyperplasia: a meta-analysis

Author

Year

Sample size (EG/CG)

Age(Y)

Intervention methods

Follow-times

outcomes

EG

CG

EG

CG

Kong Min [12]

2017

40/40

NA

NA

TUSP

TUKEP

3 months

Operation time (min); Intraoperative blood loss (ml); IPSS; Qmax;

Wang Qi [13]

2017

50/50

74.4 ± 9.8

73.1 ± 9.4

TUSP

TUPKP

3 months

Operation time (min); Intraoperative blood loss (ml); Postoperative indwelling catheter time(d); Postoperative hospital stay length(d); IPSS; Qmax; QOL; RUV; Complications

Zhou Jin [14]

2018

30/30

79.21 ± 15.37

78.86 ± 15.25

TUSP

TUPKP

NA

Operation time (min); Intraoperative blood loss (ml); Complications

Kong Qingkuo [15]

2018

107/103

NA

NA

TUSP

TURP

3 months

Operation time (min); Postoperative indwelling catheter time(d); Postoperative hospital stay length(d); IPSS; Qmax; QOL; RUV; Complications

Li Hong [16]

2018

15/15

67.4 ± 10.1

69.1 ± 10.5

TUSP

TUPKP

3 months

Operation time (min); Intraoperative blood loss (ml); Postoperative indwelling catheter time(d); Postoperative hospital stay length(d); IPSS; Qmax; QOL; RUV; Complications

Liu Shuzhi [17]

2018

10/10

72.58 ± 12.42

74.85 ± 12.28

TUSP

TUPKP

12 months

Operation time (min); Intraoperative blood loss (ml); Postoperative indwelling catheter time(d); Postoperative hospital stay length(d);

Wang Bo [18]

2019

46/46

69.3 ± 3.8

69.8 ± 3.7

TUSP

TUKEP

3 months

Postoperative indwelling catheter time(d); Postoperative hospital stay length(d);IPSS; Qmax; Complications

  1. Qmax maximum urinary flow rate, RUV residual urine volume, IPSS international prostate symptom score, QOL quality of life